Hypertension and cognitive function in the elderly

American Journal of Therapeutics

Volumn 14, Issue 6, 2007, Pages 533-554

  Cherubini, Antonio ^a   Lowenthal, David T ^b,f   Paran, Esther ^c,d   Mecocci, Patrizia ^e   Williams, Leonard S ^e   Senin, Umberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF FLORIDA   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Elderly; Hypertension; Irreversible; Leukoariosis; MRI evidence to support clinical vascular dementia; Vascular dementia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOSARTAN; METHYLDOPA; PERINDOPRIL; PLACEBO; PROPRANOLOL; RESERPINE; THIAZIDE DIURETIC AGENT;

AGING; APHASIA; ATTENTION; BATH; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BRAIN CIRCULATION; BRAIN CORTEX; BRAIN DAMAGE; BRAIN DYSFUNCTION; BRAIN FUNCTION; CALCULATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COGNITION; CONFUSION; CONGESTIVE HEART FAILURE; CONSCIOUSNESS; DAILY LIFE ACTIVITY; DECISION MAKING; DELIRIUM; DEMENTIA; DEMYELINATION; GERIATRICS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; LANGUAGE ABILITY; LOCOMOTION; LONGITUDINAL STUDY; LOW DRUG DOSE; MEMORY DISORDER; MENTAL DETERIORATION; MICROANGIOPATHY; MOTOR CONTROL; MULTIINFARCT DEMENTIA; NEUROPSYCHOLOGICAL TEST; ORIENTATION; PERSONAL HYGIENE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SENSORIMOTOR FUNCTION; SKILL; STROKE; UREMIA; VISION; WHITE MATTER;

AGED; AGING; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRAIN; CEREBROVASCULAR CIRCULATION; COGNITION; COGNITION DISORDERS; HUMANS; HYPERTENSION;

EID: 37349055076     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3180ed6b8f     Document Type: Review

References (178)

1. Lowenthal DT, Powers S, Pollock ML, et al. Interactions of Blockage and Exercise: Implications and Applications for the Elderly. The American Journal of Geriatric Cardiology. 1992;1:42-57.
2. Vogt TM, Ireland CC, Black D, et al. Recruitment of elderly volunteer for multi-center clinical trial: the SHEP pilot study. Controlled Clin Trials. 1986;7:118.
3. Kannel WB, Gordon T. Evaluation of cardiovascular risk in the elderly: The Framingham Study. Bull NY Acad Med. 1978;54:573.
4. O'Connor DW, Pollitt PA, Ilyde JB, et al. The prevalence of dementia as measured by the Cambridge Mental Disorders of the Elderly Examination. Acta Psychiatr Scand. 1989;79:190-198.
5. Ueda K, Kawano H, Hasuo Y, et al. Prevalence and etiology of dementia in a Japanese community. Stroke. 1992;23:798-802.
6. Zhang M, Katzman R, Salmon D, et al. The prevalence of dementia and Alzheimer's disease in Shangai, China: impact of age, gender, and education. Ann Neurol. 1990; 27:428-437.
7. Rocca WA, Bonaiuto S, Lippi A, et al. Provalence of clinically diagnosed Alzheimer's disease and other dementing disorders: A door to door study in Appingnano, Macerata Province, Italy. Neurology. 1990; 40:626-631.
8. Barclay LL. Survival in Alzheimer's disease and vascular dementias. Neurology. 1985;35:834.
9. Molsa PK, Martilla RJ, Rinne UK. Survival and cause of death in Alzheimer's disease and vascular dementia. Acta Neurol Scand. 1986;74:103-107.
10. Skoog I, Nilsson L, Palmertz B, et al. A population based study of dementia in 85-years olds. N Engl J Med. 1993; 153-158.
11. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama Study. Neurology. 1995;45:1161-1168.
12. Lindsay J, Ilébert R, Rockwood K. The Canadian Study of Health and Aging: Risk factors for vascular dementia. Storke. 1997;48:526-530.
13. Skoog I. Risk factors for vascular dmentia. Dementia. 1994;5:137.
14. Skoog I. Status of risk factors for vascular dementia. Neuroepidemiology. 1998;17:2-9.
15. Saunders AM, Strillmatter WJ, Schmechel D. Association of Apolipoprotein E 4 allele with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
16. Frisoni GB, Calabresi L, Geroldi C, et al. Apolipoprotein E 4 allele in Alzheimer's disease and vascular dementia. Dementia. 1994;5:240-242.
17. Strandgaard S. Autoregulation of cerebral blood flow in hypertensive patients: the modifying influence of prolonged antihypertensive treatment on the tolerance to acute, drug-induced hypotension. Circulation. 1976;53: 720-727.
18. Strandgaard S, Paulson OB. Cerebrovascular consequences of hypertension. Lancet. 1994;344:519-524.
19. Goodwin JS. Embracing Complexity: A consideration of hypertension in the very old. Journal of Gerontology A Biol Sci Med Sci. 2003;58:653-658.
20. Lowenthal DT. Commentary on "Embracing complexity: A Consideration of Hypertension in the Very Old" Journal of Gerontology A Biol Sci Med Sci. 2003;58:664-665, Discussion 669-670.
21. Vincent KR, Vincent HK, Braith RW, et al. Strength Training and Hemodynamic Responses to Exercise. Lowenthal, American Journal of Geriatric Cardiology. 2003; 12:97-106.
22. Larson EB, Kukull WA, Buchner D, et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987;107:169-173.
23. Prince MJ. The treatment of hypertension is in older people and its effect on cognitive function. Biomed Pharmacother. 1997;51:208-212.
24. Liao D, Cooper L, Cai J, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment and its control. Stroke. 1996;27:2262-2270.
25. PROGRESSIVE Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41.
26. The PROGRESS Collaborative Group, Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients with Cerebrovasular Disease. Arch Intern Med. 2003;163: 1069-1075.
27. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in ramdomized double-blind placebo controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-1351.
28. Elias MF, Wolf PA, D'Agostino RB, et al. Untreated blood pressure level is inversely related to cognitive functioning. The Framingham Study. Am J Epidemiol. 1993;138: 353-364.
29. Waldstein SR, Manuck SB, Ryan CM, et al. Neuropsychological correlates of hypertension: review and methodological considerations. Psychol Bull. 1991;110:451-468.
30. Frisoni GB, Calabresi L, Geroldi C, et al. Apolipoprotein E_4 allele in Alzheimer's disease and vascular dementia. Dementia. 1994;5:240-242.
31. Applegate WB, Pressel S, Wittes J, et al. Impact in the treatment of isolated systolic hypertension of behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994;154:2154-2160.
32. Soloman S, Hotchkiss E, Saravay SM, et al. Impairment of memory function by antihypertensive medication. Arch Gen Psychiatry. 1983;40:1109-1112.
33. van Swieten JC, Geyskes GG, Derrix MMA, et al. Hypertension in the elderly is associated with white matter lesions and congitive decline. Ann Neurol. 1991; 30:825-830.
34. Burke DM, Harrold RM. Automatic effortful semantic processes in old age: experimental and naturalistic approaches. In: Light LL, Burke DM, eds. Language, Memory and Aging. New York: Cambridge University Press; 1988:100-116.
35. Glynn RJ, Beckett LA, Hebert LE, et al. Current and remote blood pressure and cognitive decline. JAMA. 1999;281:438-445.
36. Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of β-blockers. Arch Intern Med. 1989;149:514-525.
37. Elias MF, Robbins MA, Shultz NR, et al. Clinical significance of cognitive performance by hypertensive patients. Hypertension. 1987;9:192-197.
38. Lindsay J, Hébert R, Rockwood K. The Canadian Study of Health and Aging: Risk factors for vascular dementia. Stroke. 1997;48:526-530.
39. Applegate WB, Phillips HL, Schnaper H, et al. A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch Intern Med. 1991;151:1817-1823.
40. Taylor JO, Cornioni-Huntley J, Curb JD, et al. Blood pressure and mortality risk in the elderly. Am J Epidemiol. 1991;134:489.
41. Scherr PA, Hebert LE, Smith LA, et al. Relation of blood pressure to cognitive function in the elderly. Am J Epidemiol. 1991;134:1303-1315.
42. Wallace R, Blemke JH, Morris MC, et al. Relationship of free recall memory to hypertension in the elderly. The Iowa 65+ rural health study. J Chron Dis. 1985;38:475-481.
43. Pantoni L, Garcia JH, Gutierrez JA. Cerebral white matter is highly vuinerable to ischemia. Stroke. 1996;27: 1641-1647.
44. Schlotterer G, Moscovitch M, Crapper M, et al. Visual processing deficits as assessed by spatial frequency contrast sensitivity and backward masking in normal aging and Alzheimer's disease. Brain. 1984;107:309-325.
45. Vaitkevicius PV, Fleg JL, Engl JH, et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation. 1993;88:1456-1462.
46. Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Hypertension. 1995;25:155-161.
47. Cruikshank JM, Thorp JM, Zacharis FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;i:581-584.
48. Roman GC, Tatemichi TK, Erkinijutti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDSD-AIREN International Workshop. Neurology. 1993;43:250-260.
49. Fletcher AE, Bulpitt CJ. How far should blood pressure be lowered? N Eng J Med. 1992;326:251-254.
50. Zwetnow NN. Pathophysiology of autoregulation. In: Minderhoud JM, eds. Cerebral Blood Flow: basic Knowledge and Clinical Implications. Amsterdam: Excerpta Medica; 1981.
51. Zhang M, Katzman R, Salmon D, et al. The prevalence of dementia and Alzheimer's disease in Shangai, China: impact of age, gender, and education. Ann Neurol. 1990; 27:428-437.
52. Kwok RPS, Juorio AW. Facilitating effect of insulin on brain 5-hydroxytriptamine metabolism. Neuroendocrinology. 197;45:267-273.
53. Canestrari RE. The effects of commonality on paired-associated learning in two age groups. J Genetic Psychol. 1996;108:3-7.
54. Hardy J, Adolfsen R, Alafuzoff I, et al. Transmitter deficits in Alzheimer's disease. Neurochem Int. 1985;7:545-563.
55. Hong YL. The relationship between calcium antagonist-induced hypotension and central mono aminergic system in spontaneously hypertensive rats. Int J Clin Pharmacol Ther Toxicol. 1987;11:589-597.
56. Starr JM, Whalley IJ, Deary IJ. The effects of antihypertensive treatment on congitive function: results from the HOPE study. J Am Geriatr Soc. 1996;44:411-415.
57. Overgaard JM. Cerebral blood flow and severe head injury. In: Minderhoud JM, ed. Cerebral Blood Flow: Basic Knowledge and Clinical Implication. Amsterdam, Excerpta Medica; 1981.
58. Skoog I. The relationship between blood pressure and dementia: a review. Biomed & Pharmacother. 1997;51: 367-375.
59. Erkinjuntti T, Ketonen L, Sulkava R, et al. Do white matter changes on MRI and CT differentiate vascular dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry. 1987;50:37-42.
60. Erkinjuntti T, Ostbye T, Steenhuis R, et al. The effects of different diagnostic criteria on the prevalence of dementia. N Engl J Med. 1997;337:1667-1674.
61. Skoog I, Nilsso L, Palmertz B, et al. A population based study of dementia in 85-year-olds. N Eng J Med. 1993;328: 153-158.
62. Blum JE, Javich LF, Clark ET. Rate of change on selective tests of intelligence: a twenty-five longitudinal study of aging. J Gerontol. 1970;25:171-176.
63. Rocca WA, Bonaiuto S, Lippi A, et al. Prevalence of clinically diagnosed Alzheimer's disease and other dementing disorders: A door to door study in Appignano, Maccerata Province, Italy. Neurology. 1990;40:626-631.
64. Roman, GC, Tatemichi TK, Erkinijutti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDSD-AIREN International Workshop. Neurology. 1993;43:250-260.
65. Celesia GC, Daly RF. Effects of aging on visual evoked responses. Arch Neurol. 1977;34:403-407.
66. Alberts MJ, Graffagnino C, McClenny C, et al. ApoE genotype and survival from intracerebral hemorrhage. Lancet. 1995;346:575 (letter).
67. Applegate WB, Pressel S, Eittes J, et al. (1994). Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 154:2154-60.
68. Maxwell CJ, Hogan DB, Ebly EM. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ. 1991;161:501-6.
69. Seux MI, Thijs L, Forette F, et al. Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia Project. J Hypertens. 1998;16:963-9.
70. Zhu L, Viitanen M, Guo Z, et al. Blood pressure reduction, cardiovascular diseases, and cognitive decline in the mini-mental state examination in a community population of normal very old people: a three year follow-up. J Clin Epidemiol. 1998;51:385-91.
71. Birns J, Kalra L. Blood pressure and vascular cognitive impairment: the dobate continues. J Hum Hypertens. 2006;20:1-3.
72. Launer LJ, Masaki K, Petroviecb H, et al. The association between mid-life blood pressure levels and late-life cognitive function: The Honolulu-Asia Aging Study. JAMA. 1995;274:1846-1851.
73. Feigin V, Ratnasabapathy Y, Andersn C. Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci. 2005;229-230:151-5.
74. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255-64.
75. Prince MJ, Bird AS, Blizard RA, et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ. 1996;312:801-5.
76. Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens. 2004;22:1605-12.
77. Forette I, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-1351.
78. Feldmann E. Intracerebral hemorrhage. Stroke. 1991;22: 684-491.
79. Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am Geriatr Soc. 1996;44:411-5.
80. Starr JM, Whalley LJ. Differential cognitive outcomes in the Hypertensive Old People in Edinburgh study. J Neurol Sci. 2005;229-230:103-107.
81. Alagiakrishnan K, McCracken P, Feldman H. Treatment vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline? Postgrad Med J. 2006;82: 101-5.
82. Guo Z, Vitanen M, Fratiglioni L, et al. Low blood pressure and dementia in elderly people: the Kungsholmen project. Br Med J. 1996;312:805-808.
83. Lindgren A, Roijer A, Rudling O, et al. Cerebral lesion on magnestic resonance imaging, heart disease, and vascular risk factors in subjects without stroke. Stroke. 1994;25: 929-934.
84. Brust JC. Antihypertensive therapy and cognition: more questions than answers. Stroke. 2006;37:1146.
85. Faston JD, Albers GW, Caplan LR, et al. Discussion: Reconsideration of TIA terminology and definitions. Neurology. 2004;62:529-34.
86. Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management. Raven Press New York, NY; 1990:417-431.
87. Strandgaard S, Paulson OB. Cerebrovascular consequence of hypertension. Lancet. 1994;344:519-524.
88. Granick S. Psychological test functioning. In: Granick S, Patterson RD, eds. Human Aging II: US Department of Health, Education and Iluman Welfare. Rockville, MD: DHEW Publication (HSM); 1971:71-90.
89. Sparks DL, Scheff SW, Liu H, et al. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci. 1995;131:162-168.
90. Waldstein SR, Ryan CM, Manuck SB, et al. Learning and memory function in men with untreated blood pressure elevation. J of Consulting and Clin Psychol. 1991;79: 513-517.
91. Fukuda H, Kitani M. Differences between treated and untreated hypertensive subjects in the extent of periventricular hyperintensities observed on brain MRI. Stroke. 1995;26:1593-1597.
92. Canadian Study of Health and Aging Working Group. Canadian Study of Health and Aging: study methods and prevalence of dementia. J Canad Med Assoc. 1994; 150:899-913.
93. Barbeger-Gateau P, Fabrigaule C. Disability and Cognitive Impairment in the Elderly. Disability and Rehabilitation. 1997;19:175-193.
94. Stoog I, Nilsso L, Palmertz B, et al. A population based study of demential in 85-year-olds. N Eng J Med. 1993; 328:153-158.
95. Kinkel WR, Jacobs L, Palochini I, et al. Subcortical arteriosclerotic encephalopathy (Binswanger's disease): computed tomography, nuclear magnetic resonance and clinical correlations. Arch Neurol. 1985;52:659-664.
96. Feldmann E. Intracerebral hemorrhage. Stroke. 1991;22: 684:491.
97. Senin U. The again brain. Perugia, Editriec Sigla Trc; 1983.
98. Senin U, Parnetti I, Mecocci P, et al. The aging demented brain and calcium antagonists. Intramed communications; 1994.
99. Senin U, Aisa G, Catani M, et al. Aging patient and geriatric fundamentals of geronotology and gericatrics. EdiScs; 1999.
100. Skinner H, Futerman A, Morrissette D, et al. Atenolol compared with infedipine: effect on cognitive function and mood in elderly hypertensive patients. Ann Intern Med. 1992:116:615-623.
101. Suzman RM, Willis DP, Manton KG. The oldest old. Oxford University press; 1992.
102. Ingvar DH, Lassen NA. Regulation of cerebral blood flow. In: Himwich HE, eds. Brain Metabolism and Cerebral Disorders, 2nd Ed. Ch 8, 181. New York: Spectrum Publications; 1976.
103. van Boxtel MP, Gaillard C, Houx PJ, et al. Can the blood pressure predict cognitive task performance in a healthy population sample? J Hypertension. 1997;15:1069-1076.
104. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFT): a radomised trial against atenolol. Lancet. 2002;359:995-1003.
105. Paran E, Horaf RA, Hanson A, et al. Blood pressure and cognitive functioning among independent elderly. Am Journal of Hypertension. 2003;16:818-826.
106. PROGRESSIVE Collaborative Group. Randomised trial of a perindepril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41.
107. Brun A, Englund B, Gustafason L. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiat. 1994;57:417-418.
108. Meyer JS. Improved method for non-invasive measurement of regional cerebral blood flow by 133 Xenon inhalation, Part II: measurements in health and disease. Stroke. 1978;9:205.
109. Acherio A, Hennekens C, Willett C, et al. Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension. 1996;27:1065-1072.
110. Kral VA. Senescent forgerfulness: benign or malignant. Can Med Assoc J. 1962;86:257-260.
111. Krakof LR. Renal and adrenal mechanism pertinent to hypertension in an aging population. In: Horan MJ, Steinberg GM, Dunbar JAB, et al. eds. Blood Pressure Regulation and Aging. New York: Biomedical Information Corp; 1986.
112. Zijlstra WG. Physiology of the cerebral circulation. In: Minderhoud JM, eds. Cerebral Blood Flow: Basic Knowledge and Clincal Implications. Amsterdam: Excerpta Media; 1981.
113. Mrak RE, Griffin WST, Graham DL. Aging-associated changes in human brain. J Neuropathol Exp Ncurol. 1997; 56:1269-1275.
114. Crook T, Bartus RT, Ferris SH, et al. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change-report of a National Institute of Mental Health Work Group. Dev Neuropsychol. 1986;4: 261-276.
115. Bierman EI. Aging and athcrosclerosis. In: Hazzard WR, Bierman EL, Blass JP, et al, eds. Principles of Geriatric Medicine and Gerontology, 3rd Ed. New York: McGraw-Hill; 1994.
116. Hendrie HC. Epidemiology of Dementia and Alzheimer's Disease. Am J Geriat Psychiatry. 1998;6(2 Supp 1) S3-S18.
117. Applegate WB, Pressel S, Wittes J, et al. Impact in the treatment of isolated systolic hypertension in the elderly program. Arch Intern Med. 1994;154:2154-2160.
118. Craik FIM. Two components in free recall. J Verbal Learn Verbar Behav. 1968b;7:996-1004.
119. Birren JE, Fisher M. Aging and speed of behavjor: possible consequences for psychological functioning. Ann Rev Psychol. 1995;46:329-353.
120. Hazzard WR. The scx differential in longevity. In: Hazzard WR, Bierman EL, Blass JP, et al, eds. Principles of Geriatric Medicine and Gerontology, 3rd Ed. New York: McGraw-IIill; 1994:37-47.
121. Krakof LR. Renal and adrenal mechanism pertinent to hypertension in an aging population. In: Horan MJ, Steinberg GM, Dunber JAB, et al, eds. Blood Pressure Regulation and Aging. New York: Biomedical Information Corp; 1986.
122. Gill TM, Richardson FT, Tinetti ME. Evaluating the risk of dependence in activities of daily living among community living older adults with mild to moderate cognitive impairment. J Gerontol. 1995;5: M235-241.
123. Chobanian AV. Pathophysiologic considerations in the treatment of the elderly hypertension patient. Am J Cardiol. 1983;52:49D.
124. Abrass IB. Vatecholamine levels and vascular responsiveness in aging. In: Horan MJ, Steinberg GM, Dunbar, JB, et al, eds. Blood Pressure Regulation and Aging. New York: Biomedical Information Corp; 1986.
125. Folstein M, Folstein S, McHugh P. Mini Mental State: a practical method for grading the cognitive state of patients for a clinician. J Psychiatr Res. 1975;12:189-198.
126. Forette F, Scux ML, Staessen JA, et al. Prevention of dementia in ramdomized double-blind placebo controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-1351.
127. Lipowsky ZJ. Delirum: Acute confusinal States. New York: Oxford University Press; 1990.
128. Craik FIM. Short-term memory and the aging process. In: Talland GA, ed. Human Aging and Behavior. New York: Academic Press; 1968a:131-168.
129. Stuart-Hamilton I. The psychology of aging, an introduction. London, Jessica Kingsley Publisher; 1991.
130. Burke WJ, Coronado PG, Scmitt CA, et al. Blood pressure regulation in alxheimer's disease. J Autonomic Nervous System. 1994,48:65-71.
131. Skoog I. Risk Factors for vascular dmentia. Dementia. 1994;5:137.
132. Wilkie F, Eisdorfer C. Intelligence and blood pressure in the aged. Science. 1971;172:959-962.
133. Cattel RB. Abilities: their structure, growth and action. Boston, Houghton-Mifflin; 1971.
134. Strandgaard S, Paulson OB. Cerebrovascular consequences of hypertension. Lancet. 1994;344:519-524.
135. Chimovitz MI, Awad IA, Furlan AJ. Periventricular lesions on MRI. Facts and theories. Stroke. 1989;20:963-967.
136. MacMahon S, Peto R. Cutler J, et al. Rlood pressure, stroke and conronary heart disease, part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
137. Erkinjuntti T, Gao F, Lee DH, et al. Lack of difference in brain hyperintensities between patients with early Alzheimer's discase and control subjects. Arch Neurol. 1994;51:1084-1089.
138. Linee guida 1999 per il trattamento dell'organizzazione mondiale della Sanità (OMS) c della Secietà Internazionale dell'Ipertensione (ISH). J Hypert. 1999;17:151-183.
139. Skoog I, Lernfelt B, Landahal S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996; 347:1141-1145.
140. Hatazawa J, Yamaguchi T, Ito M, et al. Association of hypertension with increased atrophy of brain matter in the elderly. J Am Geriat Soc. 1984;32:370-371.
141. Campion EW. The oldest old. N Engl J Med. 1994;330: 1819-1820.
142. Ileckbert SR, Longsteth WT, Psaty BM, et al. The association of antihypertensive examination in older adults. J Am Geriat Soc. 1997;45:1423-1433.
143. Schwartz M, Creascy H, Grady CL, et al. Computed tomographic analysis of brain morphometric in 30 healthy men, aged 21 to 81 year. Ann Neurol. 1985;17:146-157.
144. Aronson MK, Post DC, Guastadisegni P, et al. Weight changes and dementia. In: Corain B, lqbal K, Nicolini M, et al, eds. Alzheimer's Disease: Advances in Clinical and Basic Research. New York: Jolut Wiley and Son; 1993:55-63.
145. Wylie CM. Contrast in the health of elderly men and women: an analysis of recent data for Whites in the Unites States. J Am Geriatr Soc. 1984;38:670-675.
146. Salcrno JA, Murphy DGM, Horwitz B, et al. Brain atrophy in hypertension. A volumetric magnetic resonance imaging study. Hypertension. 1992;20:340-348.
147. Albert M, Smith LA, Scherr PA, et al. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci. 1991;31:167-178.
148. Moody DL, Bell MA, Challa VR. Regional cerebral vulnerability to perfusion deficits in the elderly. New Issues Neurosci. 1992;4:133-145.
149. Hauner LJ, Anersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. FURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology. 1999;52:78-84.
150. Skoog I, Nilsso L, Palmertz B, et al. A population based study of dementia in 85-year-olds. N Eng J Med. 1993;328: 153-158.
151. Havlik RJ. Antihypertensive drugs, brain structure and congnitive function: mor research is necessary. J Am Geriat Soc. 1997;45:1529-1531.
152. Cohen ML, Berkowitz BA. Vascular contraction: effective age and extracellular calcium. Res Commun Chem Pathol Pharmacol. 1979;26:433.
153. Langer DR, Ganiats TG, Barrett-Connor E. Paradoxical survival of elderlymenwith high blood pressure. Br Med J. 1989;298:1356-1358.
154. Meyer JS, Judd BW, Tawaklna T, et al. Improved cognition after control of risk factors for multi-infarct dementia. JAMA. 1986;256:2203-2209.
155. Roman GC. From UBOs to Binswanger's disease. Impact of magnctic resonance imaging on vascular dementia research. Stroke. 1996;27:1269-1273.
156. Mann SJ. Systolic hypertension in the elderly. Arch Intern Med. 1992;152:1977-1984.
157. Bryan P, Efong DO, Steward-Jones J, et al. Propranolol on tests of visual function and central nervous system activity. Br J Clin Pharmacol. 1974;1:82-84.
158. Roman GC. Form UBOs to Binswanger's discase. Impact of magnetic resonance imaging on vascular dementia research. Stroke. 1996;27:1269-1273.
159. Pantoni I, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswanger' disease. Stroke. 1995;26:1293-1301.
160. Awad IA, Spetzler RF, Hodak JA, et al. Incidental subcortical lesion identified on magnetic resonance imaging in the elderly, I: correlation with the age and cerebrovascular risk factors. Stroke. 1986;17:1084-1089.
161. Lopez OL, Beeker JT, Jungreis CA, et al. Computed tomography, but not magnetic resonance imaging-identified periventricular white matter lesions predict symptomatic cerebrovascular disease in probable Alzheimer's disease. Arch Neurol. 1995;52:659-664.
162. Farmer ME, Withe LR, Abbot RD, et al. Blood pressure and cognitive performance: The Framingham Study. Am J Epidemiol. 1987;126:1103-1114.
163. Bryan P, Efong DO, Steward-Jones J, et al. Propranolol on tests of visual function and central nervous system activity. Br J Clin Pharmacol. 1974;1:82-84.
164. Schmidt R, Fazekas F, Koch M, et al. Magnetic resonance imaging cerebral abnormalities and neuropsychologic test performance in elderly hypertensive subjects: a case-control study. Arch Neurol. 1995;52:856-910.
165. Longstreth WT, Manolio TA, Arnold A, et al. For the cardiovascular health study group. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996;27:1274-1282.
166. Hallock P, Benson IC. Studies of the elastic properties of human isolated aorta. J Clin Invest. 1937;16:595.
167. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. Washington DE: American Psychiatric Association; 1994.
168. Sixth report of the Joint National Committee on Prevention, Detection. Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2445.
169. Roman GC. From UBOs to Binxwanger's disease. Impact of magnetic resonance imaging on vascular dementia research. Stroke. 1996;27:1269-1273.
170. Salvioli G, Mussi C, Ascari S. Il Deliruim nell' Anziano. Giorn Gcront. 1998;46:423-432.
171. Kuusisto J, Koivisto K, Mykkanen L, et al. Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension. 1993;22:771-779.
172. Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, eds. Hypertension, Pathophysiology, Diagnosis and Management. New York: Raven Press; 1990: 417-431.
173. Gist YJ, Velkoff VA. Gender and aging. Demographic dimensions. Internation brief. US Department of Commerce, Economics and Statistics Administration. Bureau of Census. 1997.
174. Lopez OL, Becker JT, Jungreis CA, et al. Computed tomography, but not magnetic resonance imaging identified periventricular white matter lesions predict symptomatic cerebrovascular disease in probable Alzheimer's disease. Arch Neurol. 1995;52:659-664.
175. Hypertension Detection and Follow-up Program Cooperative Group: Blood pressure studies in 14 communities. JAMA. 1977;237:2385.
176. Hughes CP, Berg L, Danziger Wl. et al. A new clinical scale for the staging of dementia. Br J Psychiat. 1982;140: 566-572.
177. Ruitenberg A, van Sweiten JC, Wittemen JCM, et al. Alcohol consumption and risk of demential: the Rotterdam Study. Lancet. 2002;259:281-58.
178. Black S, Roman GC, Geldmacher DS, et al. Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of doneprezil in vascular dementia: positive results of a 24-week,multicenter, international, randomized, placebo-controlled clinical trail. Stroke. 2003;34:2323-30.